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Abstract
Background: Promoting Recruitment using Information Management Efficiently (PRIME) is a stepped wedge,
cluster randomised trial-within-a-trial of a complex intervention to help sites in the United Kingdom to attain their
own target number of participants to recruit to the REstart or STop Antithrombotics Randomised Trial (RESTART,
ISRCTN71907627).
Methods: Seventy-two hospital sites had opted into PRIME and were randomly allocated (using a computer-
generated block randomisation algorithm, stratified by hospital location) to one of 12 months in which a complex
intervention would be delivered. All sites began in the control state. The primary outcome is the total number of
patients randomised into RESTART per month per site, which will be analysed in a negative binomial generalised
linear mixed model. Secondary outcomes include the proportion of sites using stroke databases to identify
potentially eligible patients before PRIME, frequency of using bespoke stroke audit data exports during PRIME,
barriers to recruitment in PRIME, barriers to using the bespoke stroke audit data exports, and disadvantages of the
bespoke stroke audit exports identified by PRIME sites. PRIME began in September 2015. The last intervention will
be delivered in August 2016. Six-month follow-up will be complete in February 2017. This statistical analysis plan
was written and submitted for publication before all sites received the PRIME intervention and before outcome
data were known.
Discussion: Final results of PRIME will be analysed and disseminated in 2017.
Trial registration: Northern Ireland Hub for Trials Methodology Research SWAT repository (SWAT22).
Keywords: Statistical analysis plan, Complex intervention, Stepped wedge trial, Cluster randomised trial,
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Background
The REstart or STop Antithrombotics Randomised Trial
(RESTART, ISRCTN71907627) is an on-going rando-
mised controlled trial (RCT) of secondary prevention
after stroke due to intracerebral haemorrhage (ICH).
Promoting Recruitment using Information Management
Efficiently (PRIME) is a stepped wedge, cluster rando-
mised trial of a complex intervention to help RESTART
sites increase their recruitment and attain their own
target number of participants. Seventy-two hospital
sites that were active in RESTART in 2015 opted into
PRIME, so the trial can be considered as a study-
within-a-trial (SWAT).
Intervention
The complex intervention involves a recruitment coord-
inator discussing recruitment strategies with the princi-
pal investigator (PI) and RESTART coordinator at each
site, providing software for each site to extract from
their own stroke audit data lists of patients who were
potentially eligible for RESTART, and a second tele-
conference to review progress 6 months later. The key
components of the intervention are:
 Discussion on how staff at the site have been finding
RESTART to date
 Review of the recruitment commitment made at
the site initiation visit and how many patients
they have recruited
 Review of the information in the pre-review ques-
tionnaire about recruitment completed prior to the
recruitment review
 Explanation of the availability of bespoke stroke
audit data exports and examples provided of how
the pilot sites effectively used them
 Review of the use of a template invitation letter for
approaching prevalent patients and discussion about
how they can be used effectively in conjunction with
the bespoke stroke audit data exports
 Review of the opportunities to recruit inpatients and
outpatients at the hospital site
 Sharing of what other methods top recruiting
sites have been using to identify, consent and
randomise patients
 After the review, an email is sent to all the
collaborators at the site summarising what had been
discussed at the review, providing attendance
certificates, and giving instructions for running the
relevant bespoke stroke audit data exports
Study design
A stepped wedge design was chosen because it would
have been very difficult to apply the intervention across
all intervention clusters simultaneously in a standard,
parallel-group, cluster randomised trial design. By allow-
ing a phased introduction of the intervention in a
stepped wedge design, this meant that it was only neces-
sary to have a single PRIME coordinator to implement a
tailored intervention at each individual site; and so it
was logistically and practically easier to implement the
intervention. Furthermore, all sites will have been given
a potentially efficacious intervention by the end of the
trial, whilst the expected burden on these sites was
perceived to be low. There was also no foreseeable nega-
tive impact on patients in terms of harm or burden due
to the intervention. In addition, we would expect that
the intracluster correlation coefficient might be relatively
high in this trial as a result of high variability in average
recruitment rates between sites; leading to possibly
greater statistical power for the stepped wedge design
compared to a standard cluster trial design [1].
PRIME has a closed-cohort, stepped wedge design
whereby all participating sites are included from the
start through to the end of the trial, and we are in-
terested in assessing the recruitment rate within fixed
time periods [2]. The timing of the recruitment review
was randomised, stratified by hospital location (Scotland
versus England/Wales). This involved using computer-
generated block randomisation to randomly allocate the
72 sites to groups of six with 12 different months for the
recruitment review in one calendar year, stratified by
hospital location. The investigators, recruitment coord-
inator, and sites were all blinded to the timing of the
recruitment review until this had to be revealed in order
to organise the recruitment review. Members of staff at
each site were asked to complete questionnaires be-
fore the recruitment review and 6 months afterwards
enabling us to characterise sites, identify barriers to
recruitment, and determine any perceived disadvan-
tages to applying the intervention. Further details
about the PRIME trial design, including the sample
size calculation, can be found in the trial protocol
paper [3]. In this article we describe the statistical
analysis plan which outlines how data analysis will be
conducted at the end of the trial. The statistical
analysis plan was finalised and approved by the co-authors
on 4 April 2016.
Outcomes
Primary outcome
The primary outcome is the total number of patients
randomised into the RESTART trial per month per site.
Secondary outcomes
We will collect secondary outcomes, from the infor-
mation supplied in the questionnaires completed be-
fore, at, and 6 months after the recruitment review.
These include:
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1. Number of sites in PRIME that routinely used stroke
databases to identify potentially eligible patients
before receiving the recruitment review
2. Number of sites in PRIME that used the bespoke
stroke audit data exports, and the frequency of their
use in the 6 months after the recruitment review
3. Barriers to recruitment in PRIME, identified by sites
in the questionnaires completed before, at, and
6 months after the recruitment review
4. Barriers to using the bespoke stroke audit data
exports identified by PRIME sites at the 6-month
follow-up review
5. Disadvantages of the bespoke stroke audit
exports identified by PRIME sites at the
6-month follow-up review
General analysis principles
Analyses will include all sites as randomised unless
otherwise stated below. We will include all 72 sites that
agreed to take part in PRIME regardless of the circum-
stances of implementation of the recruitment review or
subsequent withdrawal. Any sites for which the recruit-
ment review was not implemented at the correct time or
failed to be implemented will still be included in an
intention-to-treat analysis provided that outcome data
are available.
There will be no imputation of missing data: missing
values will be left as missing for all statistical analyses.
In general, categorical data will be presented using
counts and percentages, whilst continuous variables will
be presented using the mean, median, standard deviation
(SD), minimum, maximum, first quartile, third quartile,
and number of sites with a response (n).
Outliers will be identified by viewing boxplots or
histograms and will be queried at the data checking
stage if an error is suspected. All analyses will include
outliers as standard.
All statistical tests and confidence intervals will be
two-sided. Ninety-five percent confidence intervals will
be presented with the significance of p values assessed
based on a 5% significance level. No adjustment for
multiplicity will be made in any of the analyses. There is
a single primary outcome. The secondary outcomes are
exploratory, and interpretation of their analyses will be
suitably cautious.
There will be no interim analysis of the trial data and
the final analysis will be performed after all follow-up
data have been collected.
List of analyses
Recruitment of sites and retention
An adapted Consolidated Standards of Reporting Tri-
als (CONSORT) diagram will be constructed, as rec-
ommended by Davey et al. [4] including details of the
number of sites recruited, number of site dropouts (if
any, with reasons), number receiving the intervention,
number receiving the intervention and providing
complete follow-up data, number included in the pri-
mary analysis, and any issues with intervention de-
livery or timing. In particular, we will compare the
recruitment and data collection details across the 12
randomised groups of six sites. A schematic represen-
tation of the actual study design will be reported,
similar to that shown in Fig. 1.
Descriptive analysis of baseline characteristics
Site characteristics will be summarised stratified by ran-
domised allocation group and overall. No formal statis-
tical testing will be performed at this stage. The site
characteristics will include:
1. Site location (Scotland versus England/Wales)
2. Average number of patients randomised per month
in the first 6 months of the trial, before any of the
sites were scheduled to implement the intervention
(March 2015 to August 2015)
3. Proportion of stroke inpatients, who are suitable for
follow-up, seen in clinic after hospital discharge
4. Number and percentage of sites that had
approached patients looked after by their stroke unit
in the past to invite them back to clinic with a view
to recruit them to RESTART
5. Number and percentage of sites with complete and
accurate stroke audit data
6. Number and percentage of sites already routinely
using the stroke audit data to recruit to RESTART
7. Number and percentage of sites using screening logs
as a source of information to identify eligible
RESTART patients
8. Number and percentage of sites using a database
other than the stroke audit as a source of
information to identify eligible RESTART patients
9. Number and percentage of sites using another
source of information (other than databases or
screen logs) to identify eligible RESTART patients
10. Number and percentage of sites already using other
methods to boost recruitment
11. Number and percentage of sites already identifying
barriers to finding suitable patients to recruit to
RESTART
Primary analysis of the primary outcome
To assess how the primary outcome changes over
time, the cumulative total randomisation rate since the
start of the PRIME study will be plotted in a graph for
each randomised group of six sites, with a vertical
dashed line to indicate when the sites cross over into
the intervention phase. This will be done separately
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for each of the 12 randomised groups so that we can
clearly see how the total recruitment rate for each of
the groups changes over time with reference to the
start of the intervention (Fig. 2). To provide an overall
assessment, we will also plot the cumulative total re-
cruitment rate across all sites with shading to indicate
how many sites had received the intervention up to
that point (Fig. 3).
Informed by a published method to model recruitment
[5], we will fit a negative binomial generalised linear mixed
model (GLMM) to the primary outcome, adjusting for the
fixed effects of time since start of study (in months),
season (December/January (when recruitment rates in RE-
START have been low) versus all other months), site loca-
tion (Scotland versus England/Wales), and an indicator
variable for whether the PRIME complex intervention has
Fig. 1 Schematic representation of the PRIME study
Fig. 2 Example of the line plot that will be drawn to show changes in cumulative recruitment rate over time in each randomised group of sites
(this plot does not contain any real data)
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been implemented or not (according to the planned
randomisation schedule). Site will also be included as a
random effect in the model. For the primary analysis, the
secular change in recruitment rate over time will be
adjusted for in the models using a single continuous linear
term, unless the graphs of recruitment rate over time
strongly indicate otherwise.
The results will be expressed as rate ratios with 95%
confidence intervals. The number of decimal places will
be determined by the ‘rule of four’ [6]. The estimated
time effect will also be reported from the fitted model.
The primary analysis will follow an ‘as-randomised’
principle, which means that the data will be analysed
according to the randomised timing of the recruit-
ment review rather than the actual time that the
recruitment review occurred. In addition, for the pri-
mary analysis, all sites will be included regardless of
any site withdrawals and/or compliance with the
PRIME trial procedures.
Secondary analyses of the primary outcome
There will be four separate secondary analyses of the pri-
mary outcome, which will each involve using the same
negative binomial GLMM methodology as described for
the primary outcome with the following modifications:
1. The negative binomial GLMM will additionally
include model terms representing the length of time
after the randomised introduction of the
intervention to assess whether there is a time trend
in the effect of the complex intervention on
recruitment rate. This will consist of including
categorical dummy variables in the model
representing the categories ‘3-6 months after
recruitment review’ and ‘more than 6 months after
review’; with ‘first 3 months after review’ as the
reference category
2. A per-protocol ‘actual times’ analysis will be performed:
based on the actual times of the recruitment review,
and only including those sites that continued to be
active in both the RESTARTand PRIME trials until the
end of the PRIME study period
3. The analysis will be restricted to use only data
collected within the rollout period (i.e. the period of
time when there were sites in both intervention and
control conditions). This is to reduce the risk of
confounding due to secular changes over time [2, 4],
at the expense of a reduced sample size. An
additional site-level explanatory variable will be
included in the GLMM: the average number of
people randomised per month before the PRIME
rollout phase (i.e. before the first site received
the intervention)
4. We will assess the sensitivity of the model results
with respect to different ways of specifying the
adjustment for secular trend in the models. For
example, we may model time using a categorical
factor variable or by using spline functions that
may more appropriately reflect the change in
recruitment rates observed in the graphical
analysis of primary outcome (i.e. in plots such
as those depicted in Figs. 2 and 3)
Fig. 3 Example of the line plot that will be drawn to show the change in cumulative recruitment rate over time for all sites (this plot does not
contain any real data)
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Primary outcome analysis assumptions
All analyses of the primary outcome assume that the
evaluation will not be confounded by other simultaneous
methods to boost recruitment, and that the recruitment
coordinator’s effectiveness will remain constant over
time (i.e. it will not be diluted by the increasing number
of sites that she will support over time, or influenced by
seasonal changes in trial recruitment).
Secondary outcome analyses
The PI, delegated physicians and/or research staff at
each RESTART hospital site will complete a 6-month
post-recruitment review questionnaire and the responses
will be analysed descriptively. For questions that require
a ‘yes’ or ‘no’ answer, the results will be summarised as
number (percentage). Specifically, we will report:
1. The number and percentage of sites generating and
using the stroke audit data exports
2. The number and percentage of sites experiencing any
problems running or using the audit reports out of all
those answering ‘yes’ to the question of whether they
extracted and used the stroke audit data exports
We will also report the number and percentage of sites
that had used a template invitation letter to invite poten-
tial RESTART patients to clinic before the recruitment
review took place, as recorded in the pre-recruitment
review questionnaire. (The template invitation letter was
originally sent out to RESTART sites in a substantial
amendment notification (Ref. 12/SS/0138, amendment
REC REF AM18/1) in May 2015.)
For questions in the 6-month post-recruitment review
questionnaire generating continuous data, results will be
summarised across all sites in the form of mean, median,
SD, minimum, maximum, interquartile range (IQR) and
number of sites with a response (n). In particular, we will
report summary statistics for:
1. How far back the site ran the reports to
2. How many times the site ran the reports
3. The number of patients identified by the audit reports
4. The number of eligible patients identified by the
audit reports
5. The percentage of patients who were actually
eligible out of all those identified by the audit
reports
6. The number of eligible patients who the site
contacted
7. The percentage of patients who were actually
contacted out of all those eligible
8. The number of eligible patients responding
9. The percentage of patients responding out of all
those contacted
10. The number of eligible patients who came back
to clinic
11. The percentage of patients coming back to clinic
out of all those responding
12. The number of eligible patients declining to come
back to clinic
13. The percentage of patients declining to come back
to clinic out of all those responding
14. The number of patients who were randomised as
a result of being identified by the stroke audit
data exports
15. The percentage of patients who were randomised
out of all patients who came back to clinic
Question 10 of the questionnaire asks ‘Do you think that
the reports were useful in identifying potentially eligible
patients?’ and answers are on a 5-point Likert scale ran-
ging from ‘Strongly Agree’ to ‘Strongly Disagree’. For this
outcome, the number and percentage of sites in each cat-
egory will be reported; and a bar chart will be used to dis-
play the data graphically.
The final three questions require mainly qualitative
responses and so, if appropriate, frequency tables will be
produced to show the most frequent responses.
The number of complaints from PIs and site co-
ordinators about the interventions will be reported, along
with the number of sites making at least one complaint.
The qualitative reasons for these complaints will also be
listed and categorised in a frequency table if appropriate.
We will record any costs of implementing the inter-
ventions (for the stroke audits, local RESTART investi-
gators, and participants in RESTART) if available, and
we will report corresponding summary statistics (e.g.
mean and SD).
Reporting
We will report PRIME in a manner consistent with the
adaptation of the CONSORT reporting guidelines for
cluster randomised trials [7], the guidelines for reporting
embedded recruitment trials [8], and the recommenda-
tions for reporting stepped wedge trials proposed by
Hemming et al. [1] and Davey et al. [4].
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